ATE255905T1 - Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält - Google Patents

Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält

Info

Publication number
ATE255905T1
ATE255905T1 AT97905541T AT97905541T ATE255905T1 AT E255905 T1 ATE255905 T1 AT E255905T1 AT 97905541 T AT97905541 T AT 97905541T AT 97905541 T AT97905541 T AT 97905541T AT E255905 T1 ATE255905 T1 AT E255905T1
Authority
AT
Austria
Prior art keywords
iscom
mucosa
antigen
active ingredient
matrix
Prior art date
Application number
AT97905541T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein, Bengtsson Karin Loevgren, Jill Ekstroem filed Critical Bror Morein
Application granted granted Critical
Publication of ATE255905T1 publication Critical patent/ATE255905T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT97905541T 1996-02-21 1997-02-20 Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält ATE255905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600647A SE9600647D0 (sv) 1996-02-21 1996-02-21 Ny användning
PCT/SE1997/000289 WO1997030728A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen

Publications (1)

Publication Number Publication Date
ATE255905T1 true ATE255905T1 (de) 2003-12-15

Family

ID=20401481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905541T ATE255905T1 (de) 1996-02-21 1997-02-20 Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält

Country Status (12)

Country Link
US (1) US6607732B2 (de)
EP (1) EP0889736B1 (de)
JP (1) JP2000504746A (de)
AT (1) ATE255905T1 (de)
AU (1) AU719084B2 (de)
CA (1) CA2247522C (de)
DE (1) DE69726712T2 (de)
DK (1) DK0889736T3 (de)
ES (1) ES2210495T3 (de)
NZ (1) NZ331403A (de)
SE (1) SE9600647D0 (de)
WO (1) WO1997030728A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0606481A2 (pt) 2005-01-20 2009-06-30 Isconova Ab composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina
ES2566527T3 (es) 2007-09-04 2016-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Inactivación térmica de rotavirus
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
EP2595653B1 (de) 2010-07-23 2017-06-28 Novavax AB Influenza-impfstoff
UA114086C2 (xx) 2011-05-13 2017-04-25 Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
TR201808733T4 (tr) 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
EP3082856A1 (de) 2013-12-16 2016-10-26 Zoetis Services LLC Immunogene hendra- und nipah-virus-g-glycoprotein-zusammensetzungen
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
IL277274B2 (en) 2018-03-19 2024-02-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection

Also Published As

Publication number Publication date
ES2210495T3 (es) 2004-07-01
SE9600647D0 (sv) 1996-02-21
AU719084B2 (en) 2000-05-04
CA2247522A1 (en) 1997-08-28
DE69726712T2 (de) 2004-10-07
EP0889736A1 (de) 1999-01-13
JP2000504746A (ja) 2000-04-18
AU2238597A (en) 1997-09-10
DE69726712D1 (de) 2004-01-22
NZ331403A (en) 2000-02-28
EP0889736B1 (de) 2003-12-10
CA2247522C (en) 2009-12-29
DK0889736T3 (da) 2004-04-19
US6607732B2 (en) 2003-08-19
US20020131982A1 (en) 2002-09-19
WO1997030728A1 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
ATE255905T1 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
DE69001730D1 (de) Pastenfoermige, waesserige pharmazeutische zusammensetzungen.
NO20101067L (no) Hydroksymatairesinol i forhindring av kreft
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
PT983286E (pt) Compostos de aminoalquil-glicosamina-fosfato e sua utilizacao como adjuvantes eimunoefectores
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
DE69524389D1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
ITFI920052A0 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
FI870808L (fi) 9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
NO972219D0 (no) Immunogenpreparater
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
NO983437D0 (no) Administreringsformer med umiddelbar frigivelse, samt fremgangsmÕte for fremstilling av slike
WO2000003724A1 (en) Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
FI894650L (fi) Antigen, som associerar till en human tumoer.
CY1107227T1 (el) Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889736

Country of ref document: EP

REN Ceased due to non-payment of the annual fee